ADAP soars 150% on positive Phase 1 cancer trials – is a sell-off inevitable?

Why did the ADAP surge this week? Adaptimmune Therapeutics PLC (Nasdaq: ADAP) skyrocketed 128% on Friday. Investors rallied behind ADAP because of their positive phase 1 cancer trial. ADAP’s synovial sarcoma cancer candidate (ADP-A2M4) reported a 50% response rate in patients suffering from lung, head, and neck cancers. The phase 1 trial confirmed the safeness, […]